Focal segmental glomerulosclerosis

This phase 2 trial tests an oral drug called ManNAc in 30 adults with primary focal segmental glomerulosclerosis (FSGS), a kidney disease that causes scarring and protein loss. Participants take ManNAc powder dissolved in water twice daily for 14 weeks. The study aims to see if t…

This study tests an oral medication called BI 764198 for people with a kidney condition called focal segmental glomerulosclerosis (FSGS). About 286 adults and teens will take either the study drug or a placebo daily for up to 2 years, while continuing their usual FSGS treatments.…

This study tests an experimental tablet, BI 764198, in adults and some teens with four types of kidney disease that cause protein in the urine. Participants take the drug or a placebo daily for 20 weeks while continuing their usual care. The main goal is to see if the drug lowers…

This study tests an experimental drug called APL2 for people with a kidney disease called FSGS. The goal is to see if APL2 can reduce protein in the urine, a sign of kidney damage. The trial has two parts: first, adults will receive APL2 openly; then, both adults and adolescents …

This trial tests whether a blood purification device called LIPOSORBER LA-15 can help people with focal segmental glomerulosclerosis (FSGS), a kidney disease that causes protein to leak into the urine. The study includes adults whose disease did not respond to standard treatments…

This trial tests whether a blood purification device called the Liposorber LA-15 System can help children with focal segmental glomerulosclerosis (FSGS), a kidney disease that causes protein to leak into the urine and often resists standard treatments. The device filters the bloo…

This study tests an experimental drug called praliciguat in 60 adults with a rare kidney disease called FSGS. The goal is to see if it can reduce protein in the urine, a sign of kidney damage. Participants will first receive either the drug or a placebo for 24 weeks, then everyon…

This study tests an experimental drug called EVER001 in 45 adults with three types of kidney disease (FSGS, MCD, or IgA nephropathy) that cause protein to leak into urine. Participants take the drug twice daily for a year. The main goal is to see if it safely reduces protein leve…

This study tests three experimental drugs—frexalimab, brivekimig, and rilzabrutinib—in people aged 16 to 75 with two rare kidney diseases: FSGS and MCD. The goal is to see if these drugs can reduce protein in the urine, a key sign of kidney damage, and help patients achieve remis…

This Phase 2 study tests atacicept, a drug that may reduce immune system attacks on the kidneys. About 250 adults with various autoimmune kidney diseases (like IgA nephropathy or membranous nephropathy) will receive weekly injections. Researchers will check safety and measure cha…

This study tests an oral drug called sparsentan in 67 children with certain kidney diseases that cause protein to leak into urine. The goal is to see if the drug safely reduces protein levels over 108 weeks. Participants must have a certain level of kidney function to join.

This study tests a noninvasive device that gently stimulates a nerve in the ear to help children with steroid-resistant nephrotic syndrome, a kidney condition that doesn't respond to standard steroids. The goal is to see if this approach is feasible and tolerable, and if it can r…

This study tests a non-invasive device that gently stimulates a nerve in the ear to see if it can help control nephrotic syndrome in children aged 3-17. The goal is to reduce relapses and the need for steroids or other immune-suppressing drugs. Thirty children will be randomly as…

This study tests a drug called BAT4406F in people with two rare kidney conditions: Minimal Change Disease and Focal Segmental Glomerulosclerosis. The goal is to see if it can reduce protein in the urine and prevent the disease from coming back. About 192 participants will receive…

This study tests an experimental drug, DMX-200, in people with a rare kidney condition called FSGS. The drug aims to reduce protein leakage in urine and slow down kidney damage. About 286 adults and teens (ages 12-80) who are already on standard blood pressure medication will rec…

This study tests whether the diabetes drug metformin can protect kidney cells in people with a rare kidney disease called FSGS. About 30 adults will receive either metformin or a placebo for 6 months, alongside their usual treatments. The goal is to see if metformin reduces kidne…

This study looks at whether measuring certain antibodies in the blood can help diagnose and monitor idiopathic nephrotic syndrome, a kidney condition that causes swelling and protein loss. Researchers will test blood samples from 100 adults with different forms of the disease and…

This early-stage study is testing a new oral drug called SK-09 in 72 healthy adults to see if it is safe and how the body processes it. The study is split into two parts: one where participants get a single dose, and another where they get multiple doses. No one knows who gets th…

This study investigates how changes in kidney cell metabolism relate to the rate of kidney function decline in people with ANCA vasculitis and other kidney diseases. Researchers will analyze kidney biopsy samples and blood/urine tests from 146 participants over one year. The goal…

This study is for people with rare kidney diseases like Minimal Change Disease, Focal Segmental Glomerulosclerosis, and Membranous Nephropathy. Researchers will collect health information and biological samples from 1,200 participants over many years. The goal is to better unders…

This study helps people with certain kidney diseases (like nephrotic syndrome and FSGS) find clinical trials that match their specific disease profile. Researchers analyze participants' molecular data to recommend targeted therapies in ongoing trials. The goal is to improve treat…

This study is collecting medical information and biological samples (like blood, urine, and kidney tissue) from 300 people with FSGS or MCD who have had or will have a kidney transplant. The goal is to build a research biobank called RESOLVE to help scientists study why these dis…

This study is investigating whether certain autoantibodies, especially those targeting a protein called nephrin, play a role in nephrotic syndrome, a kidney condition that causes swelling and protein loss in urine. Researchers will analyze blood and kidney tissue from 50 children…

This study aims to see if a special cell culture system can detect a substance in the blood that causes protein leakage in the urine of people with a kidney condition called nephrotic syndrome. Researchers will compare blood and urine samples from 150 participants, including pati…

This study examines 30 adults with idiopathic nephrotic syndrome, a kidney condition that can lead to kidney failure. Researchers will analyze blood immune cells and bacteria from stool and urine samples to see if changes in gut or urinary bacteria are linked to immune system pro…

Researchers at the University of Michigan and Northwestern University are interviewing children, adults, and parents of young children about their experiences with swelling caused by Nephrotic Syndrome. The goal is to develop a survey that can be used in future clinical trials to…

This study looks at why some kidney transplant patients, especially those with a kidney disease called FSGS, develop protein in their urine again after surgery. Researchers will examine blood and kidney tissue samples taken before and after the transplant to find the cause. The g…

This registry is gathering health information and biological samples from 500 people with focal segmental glomerulosclerosis (FSGS) or minimal change disease (MCD), two rare kidney conditions. Researchers will track participants over 10 years to understand how these diseases prog…